Answers are grounded in this paper and cite their sources.
Introduction: Borderline phyllodes tumor (PT) coexisting with ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) is an exceptionally rare mixed breast lesion. Due to its low incidence and compositional complexity, it poses substantial diagnostic and management challenges. We present such a case to highlight the pitfalls in preoperative diagnosis and the rationale for a multidisciplinary therapeutic strategy. Presentation of case: A 72-year-old Chinese female presented with a 2-week history of a right breast mass. Ultrasound and mammography revealed a large (52.6 mm), well-circumscribed, lobulated solid mass (BI-RADS 4A/4B), suggestive of a phyllodes tumor. Core needle biopsy returned “fibroadenoma with usual ductal hyperplasia.” Subsequent lumpectomy showed borderline PT (80%), intermediate-grade DCIS (20%), and focal Grade II invasive carcinoma of no special type (< 1%, maximal invasive diameter 3 mm). Immunohistochemistry of the invasive component: ER(−), PR(−), HER-2(3+), Ki-67 60%. Given the patient’s preference against breast conservation, a right total mastectomy with sentinel lymph node biopsy was performed (0/1 nodes positive). Final staging: pT1aN0M0, Stage IA, HER-2 overexpression subtype. No adjuvant chemotherapy, targeted therapy, or radiotherapy was given. At 12-month follow-up, no local or distant recurrence was observed. Conclusion Definitive diagnosis of PT coexisting with DCIS and IDC relies on adequate excision specimens rather than biopsy alone. Clinical management should integrate PT behavior with standard breast cancer guidelines through multidisciplinary collaboration, balancing complete oncologic control against the risk of overtreatment. Longer follow-up is warranted to confirm durable outcomes.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: